Yediyurappa appeals for support to 'Janata Curfew'

Mangaluru, Jul 11: A youth was run over by a lorry after a speeding car knocked his two-wheeler down on Netravati Bridge near Thokkottu on the outskirts of the city today.

The deceased has been identified as Ubaid (28), a resident of Bandikotya in Ullal. According to sources, he was recently engaged and was supposed to get married on July 23.

Shakir, who was with Ubaid on the two-wheeler suffered serious injuries. He was shifted to a private hospital for treatment. 

The car hit the two-wheeler when the two were heading back to Ullal from Mangaluru. 

The impact of the collision was such that Ubaid was thrown on to the road. Within a second a speeding lorry crushed him to death on the spot. 

The car driver sped away after the mishap instead of stopping to help the accident victims. However, local residents chased the car and waylaid it near Thokkotty flyover. 

The car was reportedly driven by Krishna, who works at Someshwar municipality office. He had reportedly purchased the car just two days ago. Police have taken him into custody along with another person who was also on board the car.

Traffic south police have registered a hit-and-run case and investigations are on.

Bengaluru, Jul 16: Life is a journey that cannot be imagined without traveling but the prevailing COVID-19 situation has made the whole world come to a standstill.

This pandemic has not only limited the modes of transportation for people all across India but also forces them to look for safer, convenient, and comfortable travel options. Private charter services are thus seen as the best alternative.
This is the reason the demand for availing charter services has risen dramatically over the last couple of months and encouraged airlines to either start or expand their charter services business further.

Many airlines have revamped their business strategies keeping charter services in mind and entered into this optimist business segment recently.

Star Air, the aviation arm of Indian business conglomerate - Sanjay Ghodawat Group, has entered into the charter services business to fulfill private air travel requirements.

The group previously has an experience of over six years of running helicopter charter service operations successfully under Ghodawat Enterprises Pvt Ltd.

The airline, Star Air, with its world-class fleet of three Embraer ERJ-145 aircraft (50-seater), two helicopters - Airbus H130 (6-seater) and Airbus H135 (5-seater), has the capacity to fly one anywhere at any point in time as per one's convenience that too with great comfort, luxury and complete privacy.

Star Air is a known name in the Indian aviation industry that is recognized for its unmatched safety, comfort, and on-time performance records.

It was praised in the past for connecting the unconnected by commencing commercial flight services to many Tier-II and Tier-III cities in India that were not graced with airline services before.

And now, after gaining the trust of over 1,00,000 customers from all across India and serving countless prominent VIP's, it has launched its charter service business.

It holds a valid license for charter service business and operates as per the protocols defined by the DGCA. The company has a team of experienced pilots, technicians, and staff that assures one gets a best-in-class charter service with complete safety and without any hassles.

"We are delighted to expand our airline operations by opening this private charter services. Like our scheduled commercial airline services, we are offering a world-class charter service keeping your comfort, safety, and overall flying experience in mind, said Sanjay Ghodawat, Chairman - Star Air.

This company had started its operations in January 2019 to connect the unconnected by providing world-class flight services at an affordable cost.

Since then it is continuing on its endeavour and gaining immense trust nationwide. It provides services to many Indian cities like Bengaluru, Belagavi, Indore, Kalaburagi, Mumbai, Ahmedabad, and Ajmer (Kishangarh).

Bengaluru, Mar 28: Sun Tsu, in 'The Art of War' speaks of a skilful general who can subdue his enemy without any fighting. This constitutes the ultimate triumph which is referred to as stratagem. Today, we would need one such when we are faced with the '21-day corona challenge' for India.
Nearly four weeks back, Dr Jyothsna Rao, Dr Gururaj Rao and I sat across the OPD in the afternoon at HCG Bengaluru discussing our ongoing cancer immunology research. While on this topic, we drifted into the discussion on the coronavirus. During this engaging discussion, we wondered the similarity of the enigma between the virus and cancer. I paused to ask Dr Jyothsna and Dr Guru - how we wish we could do something against this virus.
Dr Jyothsna is a PhD from NCBS and had worked under Dr Ralph Steinman, physician and researcher from Rockefeller University, who won the Nobel Prize for his discovery of the dendritic cell and its role in adaptive immunity in 2011. Dr Gururaj is a molecular and cell biologist who did his PhD at the Chapel Hill, University of North Carolina and is the Director of iCrest.
Jyothsna while hearing our perplexing conversation on the covid intervened, "Yes, surely. I think we should take a break from cancer and focus on the innate and adaptive immunity role in COVID-19."
Thus began this sincere attempt to relook the human immune system from the eyes of the COVID-19.
We have 10 types of immune cells at the least which are widely dispersed in millions across the body. When our body is invaded by a foreign organism (bacteria, fungi or virus), these cells work with each other to destroy the invader.
Now, the question is - how do the immune cells talk to each other? They use small-molecule substances called cytokines (cyto means cells; kine means movement). There are many cytokines that are involved in work on the immune system. The most relevant for viruses are interferons.
Interferons (IFN) as the name reflects have an ability to interfere with the viral activity and stop their multiplication. These specialised signal proteins are released by our cells in response to a viral attack to forewarn other cells. They help build the antiviral proteins within the cells to kill the virus as it tries to invade the new cells.
Historically, interferons are a group of cytokines known to be potent antiviral agents against viruses and a hallmark cytokine induced by the host upon viral infections. Interferons possess unique immunoregulatory activities and are signature cytokines released by (TH1) T immune cells, which are crucial in viral infections.
As the outbreak of COVID-19 grapples us, an urgent need for finding strategies to combat the virus is growing. Coronaviruses (CoVs) are a group of RNA viruses. In patients infected with coronavirus, it was indicated that the activation of the IFN does not occur until 48 hours post-infection. Thus the delayed IFN-related antiviral response by the healthy cells leads to coronavirus evade the immune response.
Numerous studies have presented the success in defeating CoVs by the direct administration of IFNs. In a combination as a concoction, it was shown to synergistically inhibit the virus replication in vitro.
Moreover, it is understood that the earlier induction of IFNs in children although they have a less developed immune system could be the reason behind the children being least affected.
The key to success in reducing the disease fatality might be the stimulation of the immune responses to trigger IFN production at the very early stages of the disease, which might be done through the administration of IFN. Despite the evidence for the efficacy of IFNs in treating CoV-induced infections, the proper dosing and ideal timing for such interventions needs to be verified in clinical trials.
For the later stages of the diseases in advance stages where patients are on ventilator and have developed respiratory distress, we propose to utilise the mesenchymal cells derived from donor bone marrow that have been known to treat acute respiratory syndrome. Mesenchymal cells are known to possess anti-inflammatory activity and thus used often in autoimmune diseases.
With this scientific background, we have activated T cells from healthy donors, in a cGMP facility at iCrest - HCG hospital with an enriched cocktail of cytokines rich in Interferons. Injections of this cocktail we believe will result in a surge of cytokines in the body of the infected person and will boost his ability to fight the virus in the early phases. We are in the initial phases of this study and hope to be ready in the coming weeks with meaningful data on its potential utility.
Currently, it awaits government approvals (Union and state) and we have applied to central drugs authority for their initial evaluation and further directions.
As my Guru often expounded the philosophy of 'Seva' - the goal of education is knowledge, the end goal of knowledge is service. In this attempt to serve our fellow humans at this brink of unprecedented crisis, medical fraternity stands with you and promises to do our best for your safety.
We assure to exhaust every bit of our spirit in this fight against coronavirus. We have lost the sight of shores and travelled thus far, but that is the mandatory first step to cross the ocean. Are we going to succeed in this battle, is something only time will answer.